Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an Medical Information Request
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • CTF 2026

Children’s Tumor Foundation’s Annual NF Conference

Jun 26-30, 2026

  1. All
  2. NF1

PDF

Adult patients' experiences with selumetinib treatment versus placebo for neurofibromatosis type 1-plexiform neurofibroma (NF1-PN) associated symptoms and their impacts: a qualitative sub-study of a phase 3, placebo-controlled trial (KOMET)

PDF

A real-world, multiple-country, prospective-cohort post-authorization safety study of selumetinib in pediatric patients with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PN): An interim analysis

PDF

Clinical and humanistic burden of adult patients with neurofibromatosis type 1 with plexiform neurofibroma (NF1-PN) in the real-world setting across four European countries: results from a real-world survey

PDF

Description of the characteristics and burden of neurofibromatosis type 1 with plexiform neurofibroma (NF1-PN) in a sample of adult patients in the USA: results from a real-world survey

HTML

Diagnosed prevalence of neurofibromatosis type 1 in the United States from 2020 to 2024

PDF

Effect of selumetinib treatment on long-term prescription pain medication utilization in adults: a retrospective study of a US claims database

PDF

Final analysis of KOMET (NCT04924608), a phase 3 study of selumetinib in adults with NF1-PN

PDF

Impact of selumetinib on pain in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (NF1-PN): an in-depth analysis from the international, phase 3, randomized, placebo-controlled KOMET triale

PDF

Natural history, management, and burden of disease in adults with NF1 and symptomatic inoperable plexiform neurofibroma (NF1-PN) in France

PDF

Neurofibromatosis type 1 in gynecological health: focused literature review and case report

PDF

Population pharmacokinetic and exposure-response analyses of selumetinib in adult patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibroma

PDF

Proteomic analysis of selumetinib effects on molecular markers of pain and tumorigenesis in adolescents with neurofibromatosis type 1 and skeletal manifestations

PDF

Psychometric validation of the PAINS-pNF target plexiform neurofibroma pain severity score using data from KOMET (NCT04924608)

PDF

Real-world NF1-PN treatment patterns in US adults with NF1-PN

PDF

Real-world outcomes of selumetinib treatment for pediatric patients with NF1-PN in the US

PDF

Selumetinib treatment in underrepresented pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas (BRIDGE Study)

HTML

The real-world effectiveness and safety of selumetinib in chinese pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN)

PDF

Adult patients' experiences with selumetinib treatment versus placebo for neurofibromatosis type 1-plexiform neurofibroma (NF1-PN) associated symptoms and their impacts: a qualitative sub-study of a phase 3, placebo-controlled trial (KOMET)

PDF

A real-world, multiple-country, prospective-cohort post-authorization safety study of selumetinib in pediatric patients with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PN): An interim analysis

PDF

Clinical and humanistic burden of adult patients with neurofibromatosis type 1 with plexiform neurofibroma (NF1-PN) in the real-world setting across four European countries: results from a real-world survey

PDF

Description of the characteristics and burden of neurofibromatosis type 1 with plexiform neurofibroma (NF1-PN) in a sample of adult patients in the USA: results from a real-world survey

HTML

Diagnosed prevalence of neurofibromatosis type 1 in the United States from 2020 to 2024

PDF

Effect of selumetinib treatment on long-term prescription pain medication utilization in adults: a retrospective study of a US claims database

PDF

Final analysis of KOMET (NCT04924608), a phase 3 study of selumetinib in adults with NF1-PN

PDF

Impact of selumetinib on pain in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (NF1-PN): an in-depth analysis from the international, phase 3, randomized, placebo-controlled KOMET triale

PDF

Natural history, management, and burden of disease in adults with NF1 and symptomatic inoperable plexiform neurofibroma (NF1-PN) in France

PDF

Neurofibromatosis type 1 in gynecological health: focused literature review and case report

PDF

Population pharmacokinetic and exposure-response analyses of selumetinib in adult patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibroma

PDF

Proteomic analysis of selumetinib effects on molecular markers of pain and tumorigenesis in adolescents with neurofibromatosis type 1 and skeletal manifestations

PDF

Psychometric validation of the PAINS-pNF target plexiform neurofibroma pain severity score using data from KOMET (NCT04924608)

PDF

Real-world NF1-PN treatment patterns in US adults with NF1-PN

PDF

Real-world outcomes of selumetinib treatment for pediatric patients with NF1-PN in the US

PDF

Selumetinib treatment in underrepresented pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas (BRIDGE Study)

HTML

The real-world effectiveness and safety of selumetinib in chinese pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN)

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 5/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States